Senores Pharmaceuticals Limited — Others, 23-07-2025: Monitoring Agency Report

Senores Pharmaceuticals has released its IPO proceeds utilization report for the quarter ended June 30, 2025. From the Rs. 500 crore IPO, the company has utilized Rs. 240.99 crore. Key progress includes fully repaying Rs. 73.10 crore of its own borrowings and Rs. 20.20 crore for subsidiary Havix. The significant Rs. 107 crore allocated for the Havix Atlanta facility's sterile injection plant remains unutilized, with commencement slated for FY26. The remaining Rs. 259.01 crore of unutilized funds are primarily held in fixed deposits. The report confirms no deviation from original IPO objectives, with minor past delays in some project completions now addressed.